35 results about "Dysthymia disorder" patented technology

Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. majorclinical depression) and dysthymia.

Provided herein are compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.

Compounds of the formula I:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.

The present invention provides a method for treating a depressive disorder which comprises a dministering a melatonin agonist alone, or in combination wit additional ant idepressant medication(s). The depressive disorder treated is one or more of major depression, dysthymia or bipolar disorder. A kit is also provided com prising one or more pharmaceutical dose units of a melatonin agonist and oneor more pharmaceutical dose units of an antidepressant. The individual dose .units may each further comprise an antidepressant or antipsychotic, and opt ionally one or more pharmaceutically active ingredients.

The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.

The present invention relates to the use of bombesin / gastrin releasing peptide antagonist in the preparation of pharmaceutical composition, said pharmaceutical composition is used for treating inflammatory diseases and immune-mediated inflammatory diseases, especially sepsis , acute lung injury and rheumatoid arthritis and for the treatment or prevention of brain disorders, preferably bipolar disorders, and in particular of different types and / or subtypes of bipolar disorders such as mania, acute mania, Severe mania, hypomania, depression, moderate depression, dysthymia, major depressive disorder, manic and / or depressive episodes, psychotic / psychotic symptoms (e.g., hallucinations, delusions), mixed bipolar states, Bipolar I disorder, bipolar II disorder, and / or rapid cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides such as gastrin-releasing peptide can be used in the treatment of inflammatory and immune-mediated inflammatory diseases and brain disorders .

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a mood disorder such as a major or minor depressive disorder or dysthymia attributed to reduced levels of Aβ protein, including Aβ1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders and methods of identifying subjects who may respond positively to such treatment by administering an agent that either prevents production of Aβ, prevents aggregation of Aβ fibrils, that increases the degradation or clearance of Aβ or that prevents or interferes with Abeta-induced neurotoxicity.

Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention relates to medicine for remedying women climacteric syndrome, osteoprosis, dysthymia, premature ovarian failure, premenstruum stress syndrome, hyperthyroidism, male and female Female / male infertility symptom, alopeia and leucotrichia and other diseases. The utility model is characterized in that the medicine comprises fatty acid within the scope of following weight parts: 8 to 32 percent of hexadecanoic acid, 11 to 35 percent of hexadecenoic acid, 13 to 33 percent of octadecenic acid, 0.3 to 2.5 percent of octadecanoic acid, 11 to 33 percent of octadecadienoic acid and 3 to 15 percent of calendic acid. Compared with other medicine, the medicine has simple component, belongs to target organ excitant, and has the function of self reversible adjustment to the second messenger substance of the organism. The invention belongs to medicine with high, safe and streamlined curative effect.